Journal article
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis
P De Cruz, MA Kamm, AL Hamilton, KJ Ritchie, EO Krejany, A Gorelik, D Liew, L Prideaux, IC Lawrance, JM Andrews, PA Bampton, S Jakobovits, TH Florin, PR Gibson, H Debinski, RB Gearry, FA Macrae, RW Leong, I Kronborg, G Radford-Smith Show all
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2015
DOI: 10.1111/apt.13353
Abstract
BACKGROUND: Crohn's disease recurs in the majority of patients after intestinal resection. AIM: To compare the relative efficacy of thiopurines and anti-TNF therapy in patients at high risk of disease recurrence. METHODS: As part of a larger study comparing post-operative management strategies, patients at high risk of recurrence (smoker, perforating disease, ≥2nd operation) were treated after resection of all macroscopic disease with 3 months metronidazole together with either azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day. Thiopurine-intolerant patients received adalimumab induction then 40 mg fortnightly. Patients underwent colonoscopy at 6 months with endoscopic recurrence asse..
View full abstractGrants
Funding Acknowledgements
AbbVie supplied the adalimumab provided in this study, and provided study support, but played no part in study design, analysis or reporting. The Gutsy Group, Gandel Philanthropy, Angior Foundation and Crohns Colitis Australia provided research support. The NHMRC supported PDC and MAK. We are grateful to colleagues and to all centres for their participation.